NEW YORK, NY / ACCESSWIRE / September 10, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Tufin Software Technologies Ltd. (NYSE:TUFN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tufin-software-technologies-ltd-loss-submission-form?prid=9193&wire=1
Lead Plaintiff Deadline: September 21, 2020
Affected investors purchased TUFN securities pursuant and/or traceable to documents issued in connection with the Company's April 2019 initial public offering and/or its December 2019 secondary public offering.
Allegations against TUFN include that: (i) Tufin's customer relationships and growth metrics were overstated, particularly with respect to North America; (ii) Tufin's business was deteriorating, primarily in North America; (iii) as a result, Tufin's representations regarding its sustainable financial prospects were overly optimistic; and (iv) as a result, the documents issued in connection with the Company's initial public offering were materially false and/or misleading and failed to state information required to be stated therein.
Ultra Petroleum Corp. (OTC PINK:UPLCQ)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/ultra-petroleum-corp-loss-submission-form?prid=9193&wire=1
Lead Plaintiff Deadline: November 2, 2020
Class Period: April 3, 2017 - August 8, 2019
Allegations against UPLCQ include that: (a) Ultra's proved reserves were materially overstated and, therefore, worth hundreds of millions of dollars less than represented; (b) Ultra's proved undeveloped reserves were of de minimis value because they contained low quality deposits that lacked a commercially viable path to development; (c) Ultra was unable to meet the production and development estimates provided to investors and such estimates lacked a reasonable basis; (d) Ultra was unable to withstand even a modest downturn in the price of natural gas because, inter alia, Ultra's business had less financial and production flexibility than claimed; and (e) Ultra did not have the technical or financial capabilities or available asset base to sustainably grow its oil and natural gas production by any meaningful amount.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fennec-pharmaceuticals-inc-loss-submission-form?prid=9193&wire=1
Lead Plaintiff Deadline: November 2, 2020
Class Period: February 11, 2020 - August 10, 2020
Allegations against FENC include that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong